- 英文名称
- Rostafuroxin
- 分子式
- C23H34O4
- 分子量
- 374.51
- 中文别名
- (3S,5R,8R,9S,10S,13S,14S,17S)-17-(呋喃-3-基)-10,13-二甲基十六氢-1H-环戊二烯并[a]菲-3,14,17-三醇; (3β,5β,14β)-21,23-环氧-24-降胆固醇-20,22-二烯-3,14,17-三醇; 化合物ROSTAFUROXIN; (3S,5R,8R,9S,10S,13S,14S,17S)-17-(Furan-3-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol; (3β,5β,14β,17α)-17-(3-Furyl)androstane-3,14,17-triol; PST2238; PST-2238; PST 2238; rostafuroxine; rostafuroxina; rostafuroxinum; 17-(3-Furyl)-5beta-androstane-3,14,17-triol; (3β,5β,14β)-21,23-Epoxy-24-Norchola-20,22-diene-3,14,17-triol
- 用途
- Rostafuroxin (PST 2238) is an orally active Na+,K+-ATPase (ATP1A1) inhibitor. It competitively inhibits Ouabain binding and signaling, antagonizes Ouabain-induced effects, and inhibits RSV-GFP expression in HSAEC and A549 cells. In vivo, it decreases SBP and improves acetylcholine-induced relaxation in rats via enhanced nitric oxide synthesis and reduced oxidative stress.